MARKET

ARCT

ARCT

Arcturus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.21
-6.27
-18.73%
After Hours: 27.92 +0.71 +2.61% 19:35 01/18 EST
OPEN
32.33
PREV CLOSE
33.48
HIGH
32.33
LOW
27.04
VOLUME
844.40K
TURNOVER
--
52 WEEK HIGH
89.18
52 WEEK LOW
24.87
MARKET CAP
717.27M
P/E (TTM)
-3.6173
1D
5D
1M
3M
1Y
5Y
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a ne...
GlobeNewswire · 15h ago
While Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders have made 872% in 3 years, increasing losses might now be front of mind as stock sheds 15% this week
It hasn't been the best quarter for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders, since the share...
Simply Wall St. · 12/25/2021 11:02
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...
New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Phar...
GuruFocus.com · 12/24/2021 05:38
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced 
Benzinga · 12/16/2021 18:08
31 Stocks Moving In Thursday's Mid-Day Session
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce proteinuria in lgA nephropathy.
Benzinga · 12/16/2021 17:14
Adagio Therapeutics, Calliditas Therapeutics leads healthcare gainers; uniQure, Regional Health Properties among major losers
Gainers: Adagio Therapeutics (NASDAQ:ADGI) +68%, Calliditas Therapeutics (NASDAQ:CALT) +28%, Assertio ASRT +17%, Aptose Biosciences (NASDAQ:APTO) +16%, Arcturus Therapeutics (NASDAQ:ARCT) +15%. Losers: uniQure QURE -25%, Regional Health Properties (NYSE:RH...
Seekingalpha · 12/16/2021 16:02
Arcturus Therapeutics Reports New Data, Provides Additional Updates From ARCT-154 And ARCT-165 Clinical Trials; Co To Evaluate Sera From Vaccinated Participants For Activity Against Omicron Variant
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and
Benzinga · 12/16/2021 13:38
BRIEF-Arcturus Therapeutics Reports New Data And Provides Additional Updates From ARCT-154 And ARCT-165 Clinical Trials
reuters.com · 12/16/2021 13:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARCT. Analyze the recent business situations of Arcturus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
41.67%Buy
8.33%Hold
25.00%Under-perform
8.33%Sell
Analyst Price Target
The average ARCT stock price target is 85.45 with a high estimate of 152.00 and a low estimate of 30.00.
High152.00
Average85.45
Low30.00
Current 27.21
EPS
Actual
Estimate
-1.72-1.29-0.86-0.43
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 177
Institutional Holdings: 19.72M
% Owned: 74.81%
Shares Outstanding: 26.36M
TypeInstitutionsShares
Increased
47
1.12M
New
34
801.21K
Decreased
42
1.93M
Sold Out
16
1.37M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.74%
Pharmaceuticals & Medical Research
-1.37%
Key Executives
Non-Executive Chairman/Independent Director
Peter Farrell
President/Chief Executive Officer/Director
Joseph Payne
Chief Financial Officer/Director
Andrew Sassine
Chief Operating Officer/Chief Scientific Officer
Padmanabh Chivukula
Other
Steven Hughes
Other
Lance Kurata
Independent Director
James Barlow
Independent Director
Edward Holmes
Independent Director
Jing Marantz
Independent Director
Magda Marquet
No Data
About ARCT
Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines company. The Company is engaged in the development of infectious disease vaccines, and significant opportunities within liver and respiratory rare diseases. The Company offers RNA medicines, RNA drug substance and nanoparticle-formulated drug products. The Company's technologies include Self-Transcribing and Replicating RNA (STARR) and lipid nanoparticle delivery system (LUNAR). The Company has developed the STARR technology platform which combines self-replicating RNA with LUNAR into a single solution. The products under developmental stage using STARR technology are ARCT-021 (LUNAR-COV19 Vaccine), LUNAR-FLU, ARCT-810 (LUNAR - ornithine transcarbamylase (OTC)) and ARCT-032 (LUNAR - cystic fibrosis (CF)). The Company has a pipeline of seven drug candidates in late-stage discovery and early stage development.

Webull offers kinds of Arcturus Therapeutics Holdings Inc stock information, including NASDAQ:ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.